Atossa Therapeutics, Inc. (ATOS)
ATOS moved a median of -0.02% 30 minutes after news, and -0.53% by the close. How ATOS actually reacts to news — the realized, point-in-time move the market made, measured across 222 labeled events over the last three years with zero look-ahead.
ATOS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 221 |
| 30-min | -0.02% | 48% | 221 |
| 60-min | -0.03% | 41% | 221 |
| to close | -0.53% | 44% | 215 |
| Middle 50% of ATOS reactions | -1.70% to +1.27% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 222 |
Half of all Atossa Therapeutics, Inc. news events land between -1.70% and +1.27% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ATOS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 40 | +0.08% | 50% | -1.31% |
| Price-target raises | 10 | -0.17% | 40% | -0.91% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ATOS ranks against every other measured name →
That’s how ATOS usually reacts — get an email when it moves on news →Email me when ATOS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ATOS's baseline. Nothing else.
Recent ATOS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value | Press release | PR Newswire | +0.00% | -0.41% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.41% | |
| Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher | Press release | PR Newswire | +1.94% | -3.40% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | -3.40% | |
| Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging | Press release | PR Newswire | +1.01% | -4.65% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | +0.00% | |
| Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | Press release | PR Newswire | -0.30% | -0.42% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.30% | -0.42% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.30% | -0.42% | |
| Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer | Press release | PR Newswire | +0.00% | +2.33% | |
| Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers | Press release | PR Newswire | +1.00% | -2.44% | |
| Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | Press release | PR Newswire | -3.58% | -6.38% | |
| Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds | Press release | PR Newswire | -5.80% | -6.34% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -5.80% | -6.34% | |
| Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial | Press release | PR Newswire | +0.00% | +3.43% | |
| Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy | Press release | PR Newswire | -0.42% | +3.76% | |
| Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer | Press release | PR Newswire | +0.00% | -0.19% | |
| Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | PR Newswire | +0.55% | +3.32% | |
| Form 10-Q ATOSSA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.55% | +3.32% | |
| Form 8-K ATOSSA THERAPEUTICS, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | +3.32% | |
| Form 8-K ATOSSA THERAPEUTICS, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | +3.32% | |
| Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women | Press release | PR Newswire | +0.36% | +4.88% | |
| Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome | Press release | PR Newswire | +3.75% | +9.94% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | +2.31% | |
| Form ARS ATOSSA THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +6.50% | +10.27% | |
| Form DEF 14A ATOSSA THERAPEUTICS, For: Mar 30 | SEC filing · Form DEF | SEC EDGAR | +6.50% | +10.27% | |
| Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update | Press release | PR Newswire | +1.16% | -9.25% | |
| Form 10-K ATOSSA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.16% | -9.25% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | -9.25% | |
| Form PRE 14A ATOSSA THERAPEUTICS, For: Mar 20 | SEC filing · Form PRE | SEC EDGAR | +0.74% | +4.47% | |
| Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives | Press release | PR Newswire | -0.10% | +0.39% | |
| Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference | Press release | PR Newswire | +1.22% | +6.76% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.65% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | +6.90% | |
| Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook | Press release | PR Newswire | -3.15% | -14.92% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -3.15% | -14.92% | |
| Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program | Press release | PR Newswire | +4.77% | +5.96% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -2.09% | +8.21% | |
| Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 | Press release | PR Newswire | +0.50% | +0.55% | |
| Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy | Press release | PR Newswire | -4.33% | -8.71% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -2.26% | |
| Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer | Press release | PR Newswire | +2.63% | +8.26% | |
| Form 8-K ATOSSA THERAPEUTICS, For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +2.63% | +8.26% | |
| Form DEF 14A ATOSSA THERAPEUTICS, For: Dec 19 | SEC filing · Form DEF | SEC EDGAR | -1.57% | -2.02% | |
| Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category | Press release | PR Newswire | -0.08% | -3.49% | |
| Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium | Press release | PR Newswire | -1.34% | -3.42% | |
| Form PRE 14A ATOSSA THERAPEUTICS, For: Dec 12 | SEC filing · Form PRE | SEC EDGAR | -1.34% | -3.42% | |
| Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Press release | PR Newswire | -0.83% | -5.75% | |
| Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen | Press release | PR Newswire | +3.35% | +3.47% | |
| Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum | Press release | PR Newswire | +0.23% | +2.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ATOS section they belong to.
Where else ATOS is measured.
ATOS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EKIMAS CORPORATION (ASNB) | 223 | 0.00% | 45% |
| OASMIA PHARMACEUTICALS AB AMERICAN DEPOSITARY SHARE (OASM) | 223 | 0.00% | 35% |
| FibroGen, Inc (FGEN) | 220 | -0.50% | 45% |
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Atossa Therapeutics, Inc.'s median reaction calculated?
Every labeled ATOS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 222 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ATOS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ATOS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.